ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors
Seasoned biotech executive with a wealth of experience and a track-record of strategic alliances in the immuno-oncology space
Barcelona, Spain, 2 December 2021: ONA Therapeutics (“ONA”), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism to treat advanced cancer, today announces the appointment of Dr Michel Detheux as Independent Chair to its Board of Directors.
